Abstract 14857: Incidence and its Characteristics of Repetition of Reintervention After Drug-Eluting Stent implantation for Femoropopliteal Lesion
Background: Although clinical trials demonstrated the superiority of Zilver paclitaxel-eluting stent (PTX), a recently developed drug-eluting stent (DES), to conventional therapy for femoropopliteal (FP) lesions, incidence and risk factors of the repetition of reintervention after DES implantation in clinical practice remained unrevealed.
Methods: This was a sub-analysis of the ZilvEr PTX for tHe Femoral ArterY and Proximal Popliteal ArteRy (ZEPHYR) study, enrolling FP lesions undergoing endovascular therapy (EVT) with DES implantation. The current study analyzed the two-year database including 583 FP lesion in 495 patients undergoing preoperative intravascular ultrasonography (IVUS) prior to DES implantation. The primary outcome measure was re-re-EVT, defined as undergoing additional EVT more than once during the two-year follow-up after DES implantation, whereas the secondary outcome measure was re-EVT, defined as undergoing additional EVT at least once during the follow-up.
Results: Twenty-eight percent of the study population had critical limb ischemia (CLI), 23% prior history of EVT, and 43% chronic total occlusion. Mean lesion length was 16 ± 10 cm, and IVUS-evaluated external elastic membrane (EEM) area was 28 ± 10 mm2. The cumulative incidence rate of re-re-EVT at 2 years was estimated to be 14%, whereas that of re-EVT was 31%. After multivariate analysis, CLI and smaller EEM area were independently associated with the outcome.
Conclusion: The incidence and risk factors of the repetition of reintervention after DES implantation for femoropopliteal lesions were revealed. The current findings suggest that DES implantation might be a careful indication in CLI cases especially with a small vessel.
Author Disclosures: O. Iida: None. M. Takahara: None. Y. Soga: None. K. Hirano: None. Y. Yamauchi: None. K. Zen: None. H. Yokoi: None. M. Uematsu: None.
- © 2016 by American Heart Association, Inc.